<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02004613</url>
  </required_header>
  <id_info>
    <org_study_id>12-1379</org_study_id>
    <nct_id>NCT02004613</nct_id>
  </id_info>
  <brief_title>Ancillary Effects of Dexmedetomidine Sedation After Cardiac Surgery</brief_title>
  <acronym>Decade</acronym>
  <official_title>Ancillary Effects of Dexmedetomidine Sedation After Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospira, now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ancillary Effects of Dexmedetomidine Sedation After Cardiac Surgery&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigator goal is to evaluate the effects of intraoperative and postoperative&#xD;
      dexmedetomidine sedation (versus placebo after cardiac surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2013</start_date>
  <completion_date type="Actual">December 18, 2020</completion_date>
  <primary_completion_date type="Actual">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Atrial Arrhythmia</measure>
    <time_frame>From the end of surgery to postoperative day 5</time_frame>
    <description>The occurrence of postoperative atrial arrhythmias</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Delirium</measure>
    <time_frame>From the end of surgery to postoperative day 5</time_frame>
    <description>The occurrence of postoperative delirium</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Acute Kidney Injury</measure>
    <time_frame>From the end of surgery to postoperative day 5</time_frame>
    <description>Acute kidney injury is defined according to Acute Kidney Injury Network (AKIN) classifications. No risk means no risk of acute kidney injury, while a higher stage means worse kidney function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Incisional Pain</measure>
    <time_frame>90 days after surgery</time_frame>
    <description>Patients were evaluated at 90 days by modified Brief Pain Inventory.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">798</enrollment>
  <condition>Heart Disease</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dexmedetomidine infusion, without a bolus dose, (or a comparable volume of placebo) will be initiated before the surgical incision at a rate of 0.1 mcg/kg/hr at the end of bypass, the dose will be increased to 0.2 mcg/kg/hr. Postoperatively patients will continue to receive the study medication at a rate of 0.4mcg/kg/hr. The study medication infusion will be continued for a total of 24 hours from the initial administration time intra-operatively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>normal saline administration matching dexmedetomidine rate of infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Dexmedetomidine</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline administration matching dexmedetomidine rate of infusion</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18-85 years old;&#xD;
&#xD;
          2. Scheduled for cardiac surgery with bypass (CABG, valve, or combined);&#xD;
&#xD;
          3. Able to provide a written informed consent;&#xD;
&#xD;
          4. Hemodynamically stable (heart rate&gt;= 55).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Sick sinus syndrome or Wolff-Parkinson-White syndrome&#xD;
&#xD;
          2. Atrio-ventricular block&#xD;
&#xD;
          3. Hypersensitivity or known allergy to dexmedetomidine&#xD;
&#xD;
          4. Hepatic disease, e.g. twice the normal level of liver enzymes&#xD;
&#xD;
          5. Atrial fibrillation within 1 preoperative month;&#xD;
&#xD;
          6. Permanent pacemaker;&#xD;
&#xD;
          7. Use of amiodarone or dexmedetomidine within the last 30 days;&#xD;
&#xD;
          8. Patients with an ejection fraction under 30% or who had severe heart failure&#xD;
&#xD;
          9. Myocardial infarction in the previÂ¬ous 7 days;&#xD;
&#xD;
         10. Body mass index =&lt; 40 (BMI= mass (kg) / height (m)2);&#xD;
&#xD;
         11. Those taking clonidine within last 48 hours.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alparslan Turan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Staff member</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic Main</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 1, 2013</study_first_submitted>
  <study_first_submitted_qc>December 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2013</study_first_posted>
  <results_first_submitted>December 18, 2020</results_first_submitted>
  <results_first_submitted_qc>March 12, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 6, 2021</results_first_posted>
  <last_update_submitted>March 12, 2021</last_update_submitted>
  <last_update_submitted_qc>March 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>Alparslan Turan</investigator_full_name>
    <investigator_title>Staff</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 12, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/13/NCT02004613/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dexmedetomidine</title>
          <description>Dexmedetomidine infusion, without a bolus dose, (or a comparable volume of placebo) will be initiated before the surgical incision at a rate of 0.1 mcg/kg/hr at the end of bypass, the dose will be increased to 0.2 mcg/kg/hr. Postoperatively patients will continue to receive the study medication at a rate of 0.4mcg/kg/hr. The study medication infusion will be continued for a total of 24 hours from the initial administration time intra-operatively.&#xD;
Dexmedetomidine: Dexmedetomidine</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>normal saline administration matching dexmedetomidine rate of infusion.&#xD;
Placebo: Normal saline administration matching dexmedetomidine rate of infusion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="400"/>
                <participants group_id="P2" count="398"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="398"/>
                <participants group_id="P2" count="396"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dexmedetomidine</title>
          <description>Dexmedetomidine infusion, without a bolus dose, (or a comparable volume of placebo) will be initiated before the surgical incision at a rate of 0.1 mcg/kg/hr at the end of bypass, the dose will be increased to 0.2 mcg/kg/hr. Postoperatively patients will continue to receive the study medication at a rate of 0.4mcg/kg/hr. The study medication infusion will be continued for a total of 24 hours from the initial administration time intra-operatively.&#xD;
Dexmedetomidine: Dexmedetomidine</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>normal saline administration matching dexmedetomidine rate of infusion.&#xD;
Placebo: Normal saline administration matching dexmedetomidine rate of infusion</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="398"/>
            <count group_id="B2" value="396"/>
            <count group_id="B3" value="794"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Only reported the mean and standard deviation for each group. Age is not available for 4 patients.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="396"/>
                    <count group_id="B2" value="394"/>
                    <count group_id="B3" value="790"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" spread="11"/>
                    <measurement group_id="B2" value="62" spread="12"/>
                    <measurement group_id="B3" value="63" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>4 patients sex data were not availiable.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="396"/>
                    <count group_id="B2" value="394"/>
                    <count group_id="B3" value="790"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="132"/>
                    <measurement group_id="B2" value="111"/>
                    <measurement group_id="B3" value="243"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="264"/>
                    <measurement group_id="B2" value="283"/>
                    <measurement group_id="B3" value="547"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <population>5 patients didn't had availiable race data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="395"/>
                    <count group_id="B2" value="394"/>
                    <count group_id="B3" value="789"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>white</title>
                  <measurement_list>
                    <measurement group_id="B1" value="365"/>
                    <measurement group_id="B2" value="363"/>
                    <measurement group_id="B3" value="728"/>
                  </measurement_list>
                </category>
                <category>
                  <title>not white</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="398"/>
                    <count group_id="B2" value="396"/>
                    <count group_id="B3" value="794"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="398"/>
                    <measurement group_id="B2" value="396"/>
                    <measurement group_id="B3" value="794"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Modified Brief Pain Inventory</title>
          <population>44 patients' baseline MBPI information was not available. Any overall severity means any pain in the last 24 hours. Any pain inference means any pain that interfering with general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life in the last 24 hours.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Overall Severity (any)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="374"/>
                    <count group_id="B2" value="376"/>
                    <count group_id="B3" value="750"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="89"/>
                    <measurement group_id="B3" value="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain interference (any)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="398"/>
                    <count group_id="B2" value="396"/>
                    <count group_id="B3" value="794"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Atrial Arrhythmia</title>
        <description>The occurrence of postoperative atrial arrhythmias</description>
        <time_frame>From the end of surgery to postoperative day 5</time_frame>
        <population>2 patients had no Atrial Arrhythmia data.</population>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine</title>
            <description>Dexmedetomidine infusion, without a bolus dose, (or a comparable volume of placebo) will be initiated before the surgical incision at a rate of 0.1 mcg/kg/hr at the end of bypass, the dose will be increased to 0.2 mcg/kg/hr. Postoperatively patients will continue to receive the study medication at a rate of 0.4mcg/kg/hr. The study medication infusion will be continued for a total of 24 hours from the initial administration time intra-operatively.&#xD;
Dexmedetomidine: Dexmedetomidine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>normal saline administration matching dexmedetomidine rate of infusion.&#xD;
Placebo: Normal saline administration matching dexmedetomidine rate of infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Atrial Arrhythmia</title>
          <description>The occurrence of postoperative atrial arrhythmias</description>
          <population>2 patients had no Atrial Arrhythmia data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="397"/>
                <count group_id="O2" value="395"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121"/>
                    <measurement group_id="O2" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis: dexmedetomidine would reduce the incidence of postoperative atrial arrhythmias.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.34</p_value>
            <method>Regression, Logistic</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.91</param_value>
            <ci_percent>97.8</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Delirium</title>
        <description>The occurrence of postoperative delirium</description>
        <time_frame>From the end of surgery to postoperative day 5</time_frame>
        <population>Delirium data is not available in 18 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine</title>
            <description>Dexmedetomidine infusion, without a bolus dose, (or a comparable volume of placebo) will be initiated before the surgical incision at a rate of 0.1 mcg/kg/hr at the end of bypass, the dose will be increased to 0.2 mcg/kg/hr. Postoperatively patients will continue to receive the study medication at a rate of 0.4mcg/kg/hr. The study medication infusion will be continued for a total of 24 hours from the initial administration time intra-operatively.&#xD;
Dexmedetomidine: Dexmedetomidine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>normal saline administration matching dexmedetomidine rate of infusion.&#xD;
Placebo: Normal saline administration matching dexmedetomidine rate of infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Delirium</title>
          <description>The occurrence of postoperative delirium</description>
          <population>Delirium data is not available in 18 patients.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="389"/>
                <count group_id="O2" value="387"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>hypothesis: Dexmedetomidine may reduce the incidence of postoperative delirium.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.026</p_value>
            <method>Regression, Logistic</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.48</param_value>
            <ci_percent>97.8</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.99</ci_lower_limit>
            <ci_upper_limit>2.23</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Acute Kidney Injury</title>
        <description>Acute kidney injury is defined according to Acute Kidney Injury Network (AKIN) classifications. No risk means no risk of acute kidney injury, while a higher stage means worse kidney function.</description>
        <time_frame>From the end of surgery to postoperative day 5</time_frame>
        <population>Acute kidney injury data is not available in 16 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine</title>
            <description>Dexmedetomidine infusion, without a bolus dose, (or a comparable volume of placebo) will be initiated before the surgical incision at a rate of 0.1 mcg/kg/hr at the end of bypass, the dose will be increased to 0.2 mcg/kg/hr. Postoperatively patients will continue to receive the study medication at a rate of 0.4mcg/kg/hr. The study medication infusion will be continued for a total of 24 hours from the initial administration time intra-operatively.&#xD;
Dexmedetomidine: Dexmedetomidine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>normal saline administration matching dexmedetomidine rate of infusion.&#xD;
Placebo: Normal saline administration matching dexmedetomidine rate of infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Acute Kidney Injury</title>
          <description>Acute kidney injury is defined according to Acute Kidney Injury Network (AKIN) classifications. No risk means no risk of acute kidney injury, while a higher stage means worse kidney function.</description>
          <population>Acute kidney injury data is not available in 16 patients.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="389"/>
                <count group_id="O2" value="389"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No risk</title>
                  <measurement_list>
                    <measurement group_id="O1" value="348"/>
                    <measurement group_id="O2" value="359"/>
                  </measurement_list>
                </category>
                <category>
                  <title>stage1</title>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Stage2</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Stage3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.14</p_value>
            <method>Regression, Logistic</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.40</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>2.34</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Incisional Pain</title>
        <description>Patients were evaluated at 90 days by modified Brief Pain Inventory.</description>
        <time_frame>90 days after surgery</time_frame>
        <population>Incisional pain at 90 days is not available in 205 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine</title>
            <description>Dexmedetomidine infusion, without a bolus dose, (or a comparable volume of placebo) will be initiated before the surgical incision at a rate of 0.1 mcg/kg/hr at the end of bypass, the dose will be increased to 0.2 mcg/kg/hr. Postoperatively patients will continue to receive the study medication at a rate of 0.4mcg/kg/hr. The study medication infusion will be continued for a total of 24 hours from the initial administration time intra-operatively.&#xD;
Dexmedetomidine: Dexmedetomidine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>normal saline administration matching dexmedetomidine rate of infusion.&#xD;
Placebo: Normal saline administration matching dexmedetomidine rate of infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Incisional Pain</title>
          <description>Patients were evaluated at 90 days by modified Brief Pain Inventory.</description>
          <population>Incisional pain at 90 days is not available in 205 patients.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="289"/>
                <count group_id="O2" value="300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.29</p_value>
            <method>Regression, Logistic</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.87</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Dexmedetomidine</title>
          <description>Dexmedetomidine infusion, without a bolus dose, (or a comparable volume of placebo) will be initiated before the surgical incision at a rate of 0.1 mcg/kg/hr at the end of bypass, the dose will be increased to 0.2 mcg/kg/hr. Postoperatively patients will continue to receive the study medication at a rate of 0.4mcg/kg/hr. The study medication infusion will be continued for a total of 24 hours from the initial administration time intra-operatively.&#xD;
Dexmedetomidine: Dexmedetomidine</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>normal saline administration matching dexmedetomidine rate of infusion.&#xD;
Placebo: Normal saline administration matching dexmedetomidine rate of infusion</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="394"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="390"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="394"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="390"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>asystol</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>heart failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>re-intervention</sub_title>
                <description>The patient went back to the operation room for redo complex mitral valve repair with plication</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <description>Elevated troponin postoperatively</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>stroke</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Transient Ischemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Hypoxemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="234" subjects_at_risk="394"/>
                <counts group_id="E2" subjects_affected="154" subjects_at_risk="390"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Clinically important hypotension</sub_title>
                <counts group_id="E1" subjects_affected="224" subjects_at_risk="394"/>
                <counts group_id="E2" subjects_affected="140" subjects_at_risk="390"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Clinically important bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="394"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="390"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Alparslan Turan</name_or_title>
      <organization>Cleveland Clinic Foundation</organization>
      <phone>216-445-9857</phone>
      <email>turana@ccf.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

